NO20074584L - Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater - Google Patents

Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater

Info

Publication number
NO20074584L
NO20074584L NO20074584A NO20074584A NO20074584L NO 20074584 L NO20074584 L NO 20074584L NO 20074584 A NO20074584 A NO 20074584A NO 20074584 A NO20074584 A NO 20074584A NO 20074584 L NO20074584 L NO 20074584L
Authority
NO
Norway
Prior art keywords
preparation
biologically active
peptidomimetic compounds
active derivatives
compounds
Prior art date
Application number
NO20074584A
Other languages
English (en)
Inventor
Carlo Scolastico
Leonardo Manzoni
Daniela Arosio
Original Assignee
Univ Degli Studi Milano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Milano filed Critical Univ Degli Studi Milano
Publication of NO20074584L publication Critical patent/NO20074584L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Oppfinnelsen angår nye sykliske peptidomimetiske forbindelser representert ved formel I inneholdende sekvensen RGD for fremstilling av passende funksjonaliserte antagonister til ?v?3- og ?v?5-integriner, og ment for eksempel for behandling av endrede angiogene fenomener eller for fremstilling av diagnostisk anvendelige forbindelser. (I)
NO20074584A 2005-03-03 2007-09-11 Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater NO20074584L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000328A ITMI20050328A1 (it) 2005-03-03 2005-03-03 Composti peptidomimetrici e preparazione di derivati biologicamente attivi
PCT/IB2006/000460 WO2006092722A1 (en) 2005-03-03 2006-03-03 Peptidomimetic compounds and preparation of biologically active derivatives

Publications (1)

Publication Number Publication Date
NO20074584L true NO20074584L (no) 2007-09-27

Family

ID=36570882

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074584A NO20074584L (no) 2005-03-03 2007-09-11 Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater

Country Status (17)

Country Link
US (3) US8636977B2 (no)
EP (2) EP1853605B1 (no)
JP (1) JP2008531677A (no)
KR (1) KR20080009681A (no)
CN (1) CN101184755A (no)
AU (1) AU2006219674A1 (no)
CA (1) CA2599876A1 (no)
DK (1) DK1853605T3 (no)
ES (1) ES2525374T3 (no)
IL (1) IL185353A0 (no)
IT (1) ITMI20050328A1 (no)
NO (1) NO20074584L (no)
PL (1) PL1853605T3 (no)
PT (1) PT1853605E (no)
RU (1) RU2007136535A (no)
SI (1) SI1853605T1 (no)
WO (2) WO2006092722A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8242105B2 (en) 2006-09-25 2012-08-14 Forschungsverbund Berlin E.V. Structural mimetics of proline-rich peptides and the pharmaceutical use thereof
EP1961759A1 (en) * 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
WO2008134761A2 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
EP2065058A1 (en) * 2007-11-28 2009-06-03 Koninklijke Philips Electronics N.V. Non-spherical contrast agents for CEST MRI based on bulk magnetic susceptibility effect
EP2127640A1 (en) 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Azide modified proteins
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
EP2453927B1 (en) 2009-07-17 2019-05-15 Technical University of Denmark Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
GB0922014D0 (en) * 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
CA2821024A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
CA2909584C (en) * 2012-06-22 2021-11-02 Mimetogen Pharmaceuticals, Inc. Synthesis of beta-turn peptidomimetic cyclic compounds
JP6793122B2 (ja) 2014-12-19 2020-12-02 ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A. 術中イメージング
KR102479601B1 (ko) 2015-12-21 2022-12-22 텍사스 테크 유니버시티 시스템 용액상 gap 펩타이드 합성을 위한 시스템 및 방법
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
AU2017376801A1 (en) 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3609892B1 (en) * 2017-04-13 2022-01-12 Bracco Imaging SpA Improved synthesis of nir fluorescent probe
EP3720854B1 (en) 2017-12-06 2021-04-21 Bracco Imaging SpA Solid phase synthesis of nir fluorescent probe
JP2021531326A (ja) * 2018-05-31 2021-11-18 ギャップ ペプチド エルエルシーGap Peptides Llc 液相ペプチド合成のための方法およびその保護戦略
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11827660B2 (en) 2019-02-01 2023-11-28 Sederma Synthesis strategy for gap protecting group
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
WO1998001795A1 (fr) 1996-07-05 1998-01-15 Edouard Pfister Dispositif horometrique
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
ITRM20020402A1 (it) 2002-07-29 2004-01-29 Sigma Tau Ind Farmaceuti Derivati fluoro-alchil-ciclopeptidi ad attivita' anti-integrine.
ITMI20031476A1 (it) * 2003-07-18 2005-01-19 Univ Degli Studi Milano Composti peptido-mimetici a struttura azabicicloalcanica comprendenti la sequenza rgd
US7371364B2 (en) 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
ITMI20032102A1 (it) * 2003-10-30 2005-04-30 Univ Degli Studi Milano Composti peptidomimetici, procedimento stereoselettivo per la loro preparazione, loro uso come intermedi di sintesi di derivati biologicamente attivi.
CN1968963A (zh) 2004-06-16 2007-05-23 通用电气医疗集团股份有限公司 基于肽的化合物
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
EP1961759A1 (en) 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
EP2358737B1 (en) 2008-10-23 2017-03-01 Steba Biotech S.A. Rgd-containing peptidomimetics and uses thereof
WO2010076334A2 (en) 2008-12-31 2010-07-08 Centre Leon Berard Intraoperative diagnosis of primary tumors and secondary tumors or metastases
EP2457593A1 (en) 2010-11-08 2012-05-30 Lykera Biomed S.A. Cyclic RGD peptides of amino acids based on thiazoles or oxazoles as selective antagonists of the alpha-v beta-3 integrin

Also Published As

Publication number Publication date
WO2006092722A1 (en) 2006-09-08
IL185353A0 (en) 2008-02-09
US8636977B2 (en) 2014-01-28
CN101184755A (zh) 2008-05-21
RU2007136535A (ru) 2009-04-10
PT1853605E (pt) 2014-12-03
WO2006092722A8 (en) 2008-01-31
EP1853603A1 (en) 2007-11-14
JP2008531677A (ja) 2008-08-14
KR20080009681A (ko) 2008-01-29
SI1853605T1 (sl) 2014-12-31
CA2599876A1 (en) 2006-09-08
EP1853605A2 (en) 2007-11-14
ITMI20050328A1 (it) 2006-09-04
WO2006095234A3 (en) 2006-12-07
WO2006095234A2 (en) 2006-09-14
PL1853605T3 (pl) 2015-02-27
US20080317668A1 (en) 2008-12-25
ES2525374T3 (es) 2014-12-23
EP1853605B1 (en) 2014-09-10
US9409951B2 (en) 2016-08-09
AU2006219674A1 (en) 2006-09-08
US20140178302A1 (en) 2014-06-26
DK1853605T3 (en) 2014-12-15
US20080139461A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
NO20074584L (no) Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20032905L (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20085110L (no) Substituerte spirosykliske CGRP-reseptorantagonister
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
BRPI0511874A (pt) derivados da pirrolopiridina
NO20061395L (no) Nye pyridinderivater
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
DK1962815T3 (da) Anvendelse af filmdannende hårplejepolymerer fra gruppen polyurethaner og farmaceutiske tilberedninger og plastre indeholdende nævnte polymerer
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
NO20052520D0 (no) Nye sulfamider
EA201000329A1 (ru) Циклические депсипептиды

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application